Nivolumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D

## Nivolumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — N/A.

## Chemical Properties

**Type**: Nivolumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — Vaccine component.